|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003250,
umls-concept:C0010453,
umls-concept:C0023473,
umls-concept:C0023516,
umls-concept:C0030705,
umls-concept:C0079189,
umls-concept:C0108779,
umls-concept:C0457343,
umls-concept:C0599161,
umls-concept:C0677856,
umls-concept:C1274040,
umls-concept:C1879547
|
|
pubmed:issue |
13
|
|
pubmed:dateCreated |
1998-12-24
|
|
pubmed:abstractText |
To investigate the potential of autologous lymphocytes to eliminate chronic myelogenous leukemia (CML) cells following activation and targeting by CD3-monoclonal antibody, we cultured Ficoll-isolated peripheral blood cells from 11 patients with CML in the chronic phase in permutated combinations of interleukin (IL)-2, CD3-monoclonal antibody (OKT3), and interferon (IFN)gamma. The efficiency of CML cell elimination was studied by means of flow cytometry and reverse transcriptase-polymerase chain reaction (RT-PCR) analysis. Cultures containing only OKT3 and IL-2, with or without IFNgamma, resulted in tumor cell reduction to the level of RT-PCR negativity. The length of the culture period required to reach a RT-PCR-negative state ranged from 3 to 33 days. A 1- to 2-log reduction in leukemic cells could be achieved by culture medium alone. In contrast, 3- to 4-log reductions in CML cells were observed following in vitro culture and ex vivo T cell activation with a given sensitivity for RT-PCR detection of 1 bcr/abl+ cell in 10(4). The feasibility of purging chronic myelogenous leukemia cells in a short time was associated with a low number of platelet counts (r=0.6457; p < 0.05). CML cell reduction was associated with expansion of CD25+/CD4+//CD8+/-/CD56+/- lymphocytes. These findings may be of relevance for immunotherapy procedures.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD3,
http://linkedlifedata.com/resource/pubmed/chemical/BCR protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Cytokines,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-gamma,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-2,
http://linkedlifedata.com/resource/pubmed/chemical/Protein-Tyrosine Kinases,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-abl,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-bcr
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0301-472X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
26
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1265-70
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:9845383-Adult,
pubmed-meshheading:9845383-Aged,
pubmed-meshheading:9845383-Antibodies, Monoclonal,
pubmed-meshheading:9845383-Antigens, CD3,
pubmed-meshheading:9845383-Cytokines,
pubmed-meshheading:9845383-Female,
pubmed-meshheading:9845383-Flow Cytometry,
pubmed-meshheading:9845383-Humans,
pubmed-meshheading:9845383-Immunophenotyping,
pubmed-meshheading:9845383-Interferon-gamma,
pubmed-meshheading:9845383-Interleukin-2,
pubmed-meshheading:9845383-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:9845383-Lymphocyte Activation,
pubmed-meshheading:9845383-Male,
pubmed-meshheading:9845383-Middle Aged,
pubmed-meshheading:9845383-Protein-Tyrosine Kinases,
pubmed-meshheading:9845383-Proto-Oncogene Proteins,
pubmed-meshheading:9845383-Proto-Oncogene Proteins c-abl,
pubmed-meshheading:9845383-Proto-Oncogene Proteins c-bcr,
pubmed-meshheading:9845383-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:9845383-Tumor Cells, Cultured
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
Activation of autologous lymphocytes of patients with chronic myelogenous leukemia in the chronic phase with cytokines and CD3 monoclonal antibody results in bcr/abl- blood leukocyte cultures as determined by reverse transcriptase-polymerase chain reaction.
|
|
pubmed:affiliation |
Department of Hematology, Oncology and Transfusion Medicine, Medical School Benjamin Franklin, Free University Berlin, Germany.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
